We present a case of a preteen with autism spectrum disorder and severe self-injurious behavior who developed neuroleptic malignant syndrome on antipsychotics and required urgent electroconvulsive therapy and continued maintenance electroconvulsive therapy for ongoing clinical stability.
From the *Department of Psychiatry, Hospital Universitari i Politècnic La Fe, Valencia, Spain
†Department of Psychiatry, University of British Columbia
‡Child and Adolescent Mental Health Programs, BC Children's Hospital
§Department of Pharmacy, Children's and Women's Health Centre of British Columbia
∥Non-Invasive Neurostimulation Therapies Laboratory, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Received for publication October 16, 2018; accepted February 20, 2019.
Reprints: Fidel Vila-Rodriguez, MD, PhD, Department of Psychiatry, University of British Columbia, Detwiller Pavilion 2255 Wesbrook Mall, Vancouver, BC, Canada V6T 2A1 (e-mail: email@example.com).
F.V.-R. reports research grants from CIHR, Brain Canada, Michael Smith Foundation for Health Research, and Vancouver Coastal Health Research Institute. He reports receiving in-kind equipment support for this investigator-initiated trial from Mag Venture and has been on an advisory board for Janssen. D.E. has received funding from Teva Pharmaceuticals Inc for development of an attention-deficit/hyperactivity disorder training module for pharmacists and the public. For the remaining authors, none were declared.
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.ectjournal.com).